Spectral and Metra Biosystems to merge operations
This article was originally published in Clinica
Executive Summary
In an attempt to add critical mass to two ailing small point-of-care diagnostics companies, Spectral Diagnostics and Metra Biosystems are to merge in a transaction which will result in annual sales of around $13 million and cash resources of more than $32 million. The transaction will end with Spectral holding 51% of the as yet unnamed new company and Metra controlling the remainder.